Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer

Overall, PARP inhibitor maintenance therapy appeared to be generally tolerated in older patients in this real-world cohort. However, older individuals who received olaparib monotherapy experienced a significantly higher incidence of clinically significant neutropenia, indicating the need for careful monitoring and individualized dose management in this subgroup.